Otros idiomas Purple Biotech Ltd

Acciones

PPBT

IL0007650166

Diferido TEL AVIV STOCK EXCHANGE Otros sitios de cotización 12:17:03 21/05/2024			Varia. Cinco días.	Varia. 1 de enero.
17,6 ^ILa	-5,88 %		-3,83 %	-44,83 %

25/04	El estudio aleatorizado de fase 2 sobre el cáncer de páncreas CM24 de Purple Biotech Ltd. seleccionado como presentación tardía de pósteres en la reunión anual ASCO 2024	CI
14/03	Purple Biotech informa de una prueba preclínica de concepto para su tecnología de plataforma de anticuerpos triespecíficos	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Purple Biotech Ltd.'s Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting	25/04
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024	28/03
Purple Biotech Reports Preclinical Proof of Concept for Its Tribody Platform Technology	14/03
Purple Biotech : Immediate Report	06/03
6K:Fourth Quarter and Full-Year 2023 Financial Results	05/03
Purple Biotech Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	05/03
Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results	05/03
Purple Biotech Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	05/03
Purple Biotech Presents Data of Its Phase 1 Head & Neck Cancer of NT219 in Combination with Cetuximab At ESMO TAT Congress 2024	27/02
Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024	27/02
Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial	13/02
Purple Biotech Reaches Recommended Phase 2 Dose for NT219	01/02
Purple Biotech Ltd. Announces Executive Changes	20/12
Purple Biotech Ltd. Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial	14/12
Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial	14/12
Papillary Thyroid Cancer Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	30/11
Purple Biotech Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	21/11
Purple Biotech Reports Third Quarter 2023 Financial Results	21/11
Purple Biotech Fortifies NT219 Patent Protection	02/11
Purple Biotech : Other Report or Announcement	31/10/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Purple Biotech Ltd

Acciones

PPBT

IL0007650166

Otros idiomas

Filtros